

## REFERENCES

- Abby, J. & Oliver, P. 2009. Physical Principles of Intra- Arterial Blood Pressure Measurement: *ATOTW*, 137.
- Agency for Healthcare Research & Quality. 2011. ACEIs, ARBs, or DRI for adults with hypertension. *Journal of Agency for Healthcare Research & Quality*.
- Albert N M., Yancy C. W., Liang L., & Zhao X., 2009. Use of aldosterone antagonists in heart failure. *JAMA*. **(15) 302**:1658-65
- American College of Physician. 2004. Living with Hypertension. *American College of Physicians*.
- American Heart Association. 2014. Understanding and Managing High Blood Pressure. AHA/ASA.
- Badyal D.K., Lata H. & Dadhich A.P. 2003. Animal models of hypertension & effect of drugs. *Indian J. Pharmacol.*, **35**, 349–362.
- Bernard H. 2009. The renal renin-angiotensin system. *Advances in Physiology Education* **(33)**4, 270-274
- Bradley T. E., Jessica R. C., Priestleya & Oleg P. 2014. Mutation of *Plekha7* attenuates salt-sensitive hypertension in the rat. *PNAS* **(111)**35 12817–12822
- Brenner B. M & Taal M. W., 2004. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. *Kidney Int* **(57)**, 1803–1817
- British Hypertension Society. 2008. Angiotensin Receptor Blockers (ARBs). British Hypertension Society.
- Brook RD, Bard RL, Burnett RT, Shin HH, Vette A, Croghan C, et al. 2014. Hemodynamic, Autonomic, and Vascular Effects of Exposure to Coarse Particulate Matter Air Pollution from a Rural Location. *Occup Environ Med* **(68)**:224–230.
- Brook, R.D., & Julius S. 2000. Autonomic imbalance, hypertension, & cardiovascular risk. *Am J Hypertension*. **13**, 112S-122S.
- Cai, H., & Harrison, D.G. 1987. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res.*, **87**(4), 840.

- Charkoudian, N., & Rabbitts, J. A. 2009. Sympathetic Neural Mechanisms in Human Cardiovascular Health and Disease. *Mayo Clinic Proceedings*, 84(9), 822–830.
- Chen. 2010. Calcium channel blockers versus other classes of drugs for hypertension. *The Cochrane Library*, issue 8.
- Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Roccella, E.J. 2003. [Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, & Treatment of High Blood Pressure](#). *Hypertension*, 42(6), 1206–52.
- CHRC. 2007. Managing Hypertension in Primary Care in the Caribbean. *Caribbean Health Research Council*.
- Cohen, D., Marsh, T., Williamson, S., Golinelli, D., & McKenzie, T. L. 2009. Impact and Cost-Effectiveness of Family Fitness Zones: A Natural Experiment in Urban Public Parks. *Health & Place*, 18(1), 39–45.
- Cook, NR, Cutler, J.A., Obarzanek, E., Buring, J.E., Rexrode, K.M., Kumanyika, S.K. 2007. Longterm effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). *BMJ.*, 334, 885–888.
- Cornelissen, V.A. & Fagard, R.H. 2005. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms & cardiovascular risk factors. *Hypertension.*, 46(5), 667–675.
- Danai, T., Anastasakis, E., Papadogiannis, D. E. 2008. Beta-blockers in the treatment of hypertension. *Hellenic J Cardiol.*, 48, p: 37-4.
- Danai. 2008. Beta-Blockers in the Treatment of Hypertension: Latest Data & Opinions. *Hellenic J Cardiol.*, 48, 37-47.
- Dickinson, H.O., Mason, J.M., Nicolson, D.J., Campbell, F, Beyer, F.R., Cook, J.V., 2006. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens.*, 24, 215–233
- Dornas, W.C., Silva, M.E. 2011. Animal models for the study of arterial hypertension. *J. Biosci.*, 36, 731–737. doi: 10.1007/s12038-011-9097-y.
- Ezzati, M, Lopez AD, Rodgers, A, Ver, Hoorn S, Murray, C.J. 2002. Comparative Risk Assessment Collaborating Group. Selected major risk factors & global & regional burden of disease. *Lancet.*, 360 : 1347-60.
- ESH/ESC. 2013. Guidelines for the management of arterial hypertension. *Journal of Hypertension* (31):1281–1357

Food and Drug Administration. 2014. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval.\

Frohlich, F. Bazhenov, M. Sejnowski, T. J. 2008. Pathological Effect of Homeostatic Synaptic Scaling on Network Dynamics in Diseases of the Cortex, *The Journal of Neuroscience*, 28,(7)

Fujita T and Masaomi N., 2008. Activation of the Renin-Angiotensin System and Chronic Hypoxia of the Kidney *Hypertension Research* (31), 175–184

Funk D. J., Jacobsohn E., & Kumar A. 2013. The Role of Venous Return in Critical Illness and Shock—Part I: Physiology. *Crit Care Med* (41):255–262

Garovic V. D., ; Anthony A. H., Stephen T. T. 2006. Monogenic Forms of Low-Renin Hypertension. *Nat Clin Pract Nephrol* 2(11):624-630.

Gnonlonfin, G.J.B., Adjovi, J., Gbaguidi, F., Gbenou, Katerere, D., Brimer. L., & Sann, L. 2011. Scopoletin in cassava products as an inhibitor of Aflatoxin production. *Journal of Food Safety*.1-6, doi:10.1111/j.1745-4565.2011.00334.x.

Grassi, G., Seravalle, G, Calhoun, D.A., Bolla, G.B., Giannattasio, C., Marabini, M. 1994. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. *Circulation*. 90, 248–253.

H. G. Byun, 2002. *J. Biochemistry & Molecular Biology*. 35(2), 239- 243.

Hongwei M., Dunquan X., &Yaqiong W., 2015. To decipher the hypoxic pulmonary hypertension: Vascular heterogeneity and the hypothesis of hypoxic responsive threshold. *Journal of Medical Hypotheses and Ideas* (9) 1, pp 29–37.

Isbell B.F., Franke A, & Fielding R. M. 2008. Pharmacokinetic study of Noni fruit extract *J Diet Suppl.* (4) 5 :373-82

Jendzjowsky, N. G., Just, T. P., Jones, K. E., & DeLorey, D. S. 2014. Acute tetrahydrobiopterin supplementation attenuates sympathetic vasoconstrictor responsiveness in resting and contracting skeletal muscle of healthy rats. *Physiological Reports*, 2(10), e12164.

Josep, S. 2011. [\*Continuous non-invasive blood pressure estimation\*](#). Zurich: ETHZ PhD dissertation.

Juan, M. S. 2007. The Challenge of Genetic Studies in Hypertension. *American Heart Association* (10). doi: 10.1080/19390210802519671.

- Kearney, P.M., Whelton, M., Reynolds, K., Whelton, P. K., & He, J. 2004. Worldwide prevalence of hypertension: a systematic review. *Journal of Hypertension.*, **22**, 11–19.
- Klabunde, R.E., 2007. ["Cardiovascular Physiology Concepts – Pulse Pressure"](#). Retrieved 2008-10-02. [Archived version 2009-10-03](#).
- Klabunde, R.E., 2007. [Cardiovascular Physiology Concepts – Mean Arterial Pressure](#). Retrieved 2008-09-29. [Archived version 2009-10-03](#).
- Klabunde, RE (2007). [Cardiovascular Physiology Concepts – Mean Arterial Pressure](#) Retrieved 2008-09-29.[Archived version 2009-10-03](#).
- Klinger J. R., Steven H. A., Mark T. G. 2013.Nitric Oxide Deficiency and Endothelial Dysfunction in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine* (188) pp. 639-646.
- Salina Y. S., 2014. Angiotensin converting enzyme gene polymorphism studies: A case-control study. *Saudi Journal of Biological Sciences* (22) 3, pp 327-331
- Kumar, R., Kumar, A., Sharma, R., Baruwal, A., 2011. Pharmacological review on Natural ACE inhibitors. *Der Pharmacia Lettre.*, **2**(2): 273-293.
- Kurdekar, R.R., Hegde, G.R., Kulkarni, M. V., & Mulgund, G.S., 2013. Isolation & characterization of scopoletin- an anticancerous compound from the bark of *hymenodictyon bovatum* wall. *International Journal of Pharmaceutical & Phytopharmacological Research.*, (eIJPPR), 1-8.
- Laursen, J.B., Rajagopalan, S., Galis, Z., Tarpey, M., Freeman, B.A., Harrison, D.G. 1997. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. *Circulation.* **95**, 588-93.
- Lijnen P, Petrov V. 2000. Induction of cardiac fibrosis by aldosterone. *J Mol Cell Cardiol.* 32, p:865-79.
- Malik, A., Kushnoor, A., Saini, V., Singhal, S., Kumar, S., & Yadav, Y.C., 2011. In vitro antioxidant properties of Scopoletin. *J. Chem. Pharm. Res.*, 3(3) p:659-665.
- Manimunda, S. P., Sugunan, A. P., Benegal, V., Balakrishna, N., Rao, M. V., & Pesal, K. M., 2011. Association of hypertension with risk factors & hypertension related behaviour among the aboriginal Nicobarese tribe living in Car Nicobar Isl&, India. *Indian J Med Res* 133, pp 287-293.

- Manoocher S., 2015. *Insulin resistance and hypertension: new insights*. *Kidney International* (87), 497–499
- Maricica P., Ramzi K., Paul B., and, Kenneth N. 2014. The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling. *International Journal of Inflammation* (2014), 1-13.
- Mogana, 2013. Anti-Inflammatory, Anticholinesterase, & Antioxidant Potential of Scopoletin Isolated from *Canarium patentinervium* Miq. (Burseraceae Kunth). *Evidence-Based Complementary & Alternative Medicine*. Vol. 2013, 1-7. Doi : org/10.1155/2013/734824.
- Mogana, R., Jin, K.T., & Wiart, C., 2013. Anti-Inflammatory, Anticholinesterase, & Antioxidant Potential of Scopoletin Isolated from *Canarium patentinervium* Miq. (Burseraceae Kunth). *Corporation Evidence-Based Complementary & Alternative Medicine*. Volume 2013, 7 pages doi.org/10.1155/2013/734824.
- Mulvany, M.J., Aalkjaer, C. 1990. Structure & function of small arteries. **70**, 921-61.
- Nakazono, K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. 1991. Doessuperoxide underlie the pathogenesis of hypertension. *Proc Natl Acad Sci U S A.*, **88** (8), 10045.
- Nandini S., 2014. Essential Hypertension. *Pharm. Sci. & Res* (9)6 , pp 305-307
- Oparil S., Zaman M. & Calhoun D. A., 2003. Pathogenesis of hypertension. *Ann Intern Med* (139) pp:761-776.
- Peterson, J. K., Harrison, H. F., Michal, D. M., Snook, M. E. 2003. Biological Contents of Scopolin & Scopoletin in Sweet Potato Clones. *Hort Science.*, **38** (6).1129-1133.
- Romero, R., Bonet, J., de la Sierra A, Aguilera, M.T. 2007. Undiagnosed obesity in hypertension: clinical & therapeutic implications. *Blood Press.*, **16**, 347–353.
- Sever, P.S. & Messerli, F.H., 2011. Hypertension management 2011: optimal combination therapy. *European Heart Journal.*, **32**, 2499–2506. doi:10.1093/eurheartj/ehr177.
- Surendhra G. and Jayanthi, T. 2014. Cuff less Continuous Non-Invasive Blood Pressure Measurement Using Pulse Transit Time Measurement. *International Journal of Recent Development in Engineering and Technology* (2), 1
- Švíglerová, J., Kuncová, J., Nalos, K., Tonar, Z., Rajdl, D., M. Steng, I., 2010. Cardiovascular Parameters in Rat Model of Chronic Renal Failure Induced by Subtotal Nephrectomy. *Physiol. Res.* **59** (Suppl. 1): S81-S88.
- Textbook of Medical Physiology, 7th Ed., Guyton & Hall, Elsevier-Saunders, [ISBN 0-7216-0240-1](#), 220.

- Tkachenko, B.I., Evlakhov, V.I., Poyasov, I.Z., 2002. Independence of changes in right atrial pressure & central venous pressure. *Bull. Exp. Biol. Med.* **134** (4): 318–20. doi:[10.1023/A:1021931508946](https://doi.org/10.1023/A:1021931508946). PMID [12533747](https://pubmed.ncbi.nlm.nih.gov/12533747/).
- Vernerová, Z., Kujal, P., Kramer, H., Bäcker, A., Červenka, Vaněčková, I., 2009. End-Organ Damage in Hypertensive Transgenic Ren-2 Rats: Influence of Early & Late Endothelin Receptor Blockade. *Physiol. Res.* **58** (Suppl. 2): S69-S78.
- Weber M. A., Ernesto L. S., William B. W., 2014. Clinical Practice Guidelines for the Management of Hypertension in the Community. *American Society of Hypertension and the International Society of Hypertension* (**10**), 1111
- Whelton, P.K. 1994. Epidemiology of hypertension. *Lancet.*, **34**(6), 101
- Whelton, P.K., He. J. 1997. Epidemiology & prevention of 1. hypertension. *Med Clin North Am.*, **81**, 1077-97.
- World Health Organization, 2008. Chronic diseases & their common risk factors. *World Health Organization Sheet Fact*, 3-5.
- Xiaoping, 2009. Diuretics. *Department of Pharmacology*, 154-156.
- Yousef, W. M., Omar, A. H., Morsy, M. D., El-Wahed, M.M.A., Ghanayem, N.M. 2005. Review of the mechanism of action of calcium channel blockers in the treatment of diabetic nephropathy. *Int J Diabetes & Metabolism*, **13**, 76-82.
- Yuliandra. 2014. Comparative effectiveness of defatted hypotensive crude extract, ethyl acetate and butanolic fractions of cassytha filiformis l. On different models of hypertensive rats. *World journal of pharmacy and pharmaceutical sciences* 3(**12**):200-208

